| Sep 10 |
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
|
| Sep 7 |
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
|
| Sep 4 |
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
|
| Sep 3 |
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
|
| Sep 3 |
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
|
| Aug 16 |
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
| Aug 9 |
Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 8 |
Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold
|
| Aug 7 |
Stoke Therapeutics GAAP EPS of -$0.46, revenue of $4.83M
|
| Aug 7 |
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
|
